GDRX Stock Forecast 2025-2026
Distance to GDRX Price Targets
GDRX Price Momentum
🤔 Considering GoodRx (GDRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest GDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, GDRX has a bullish consensus with a median price target of $6.50 (ranging from $4.75 to $9.00). The overall analyst rating is Buy (7.8/10). Currently trading at $4.42, the median forecast implies a 47.1% upside. This outlook is supported by 9 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Scott Schoenhaus at Keybanc, projecting a 103.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDRX Analyst Ratings
GDRX Price Target Range
Latest GDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $8.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.25 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $6.00 |
| Dec 17, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $6.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $7.00 |
| Nov 11, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $6.00 |
| Aug 16, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $10.00 |
| Aug 9, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.00 |
| Aug 9, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $8.50 |
| Jun 10, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $9.50 |
| May 23, 2024 | RBC Capital | Mark Mahaney | Outperform | Upgrade | $10.00 |
| May 20, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $10.00 |
| May 16, 2024 | Raymond James | John Ransom | Outperform | Upgrade | $10.00 |
| May 16, 2024 | TD Cowen | Charles Rhyee | Buy | Maintains | $16.00 |
| Apr 10, 2024 | Keybanc | Scott Schoenhaus | Overweight | Upgrade | $9.00 |
| Mar 25, 2024 | Wells Fargo | Stan Berenshteyn | Overweight | Upgrade | $10.00 |
| Mar 8, 2024 | RBC Capital | Sean Dodge | Sector Perform | Reiterates | $8.00 |
| Mar 1, 2024 | JP Morgan | Lisa Gill | Overweight | Upgrade | $10.00 |
| Mar 1, 2024 | UBS | Eric Sheridan | Neutral | Maintains | $8.00 |
| Mar 1, 2024 | Truist Securities | Jailendra Singh | Hold | Maintains | $8.00 |
GoodRx Holdings Inc. (GDRX) Competitors
The following stocks are similar to GoodRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GoodRx Holdings Inc. (GDRX) Financial Data
GoodRx Holdings Inc. has a market capitalization of $1.70B with a P/E ratio of 110.5x. The company generates $792.32M in trailing twelve-month revenue with a 2.1% profit margin.
Revenue growth is +1.0% quarter-over-quarter, while maintaining an operating margin of +19.4% and return on equity of +2.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
GoodRx Holdings Inc. (GDRX) Business Model
About GoodRx Holdings Inc.
Digital healthcare platform for affordable prescriptions.
GoodRx operates by aggregating pricing data from over 70,000 pharmacies, allowing users to find discounts, coupons, and compare medication prices. The company generates revenue primarily through partnerships with pharmacies and pharmaceutical companies, receiving fees for each transaction facilitated via its platform.
Headquartered in Santa Monica, California, GoodRx addresses the critical issue of high medication costs affecting millions of Americans, particularly those without insurance. The platform aims to enhance transparency in drug pricing, making healthcare more accessible and manageable for consumers.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
738
CEO
Ms. Wendy Barnes
Country
United States
IPO Year
2020
Website
www.goodrx.comGoodRx Holdings Inc. (GDRX) Latest News & Analysis
GoodRx report reveals women will spend $8.8 billion more than men on out-of-pocket prescription costs in 2024, highlighting a significant gender cost disparity in healthcare.
GoodRx's report highlights a significant gender disparity in prescription costs, indicating potential shifts in consumer behavior and spending. This could impact healthcare stocks and market dynamics.
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
16 days agoGoodRx Holdings Inc. reported Q4 revenue of $198.6 million, a 1% increase year-over-year, but fell short of management guidance and consensus estimates.
GoodRx's Q4 revenue miss signals potential growth challenges, which could impact investor confidence and future stock performance.
GoodRx Holdings, Inc. will hold its Q4 2024 Earnings Conference Call on February 27, 2025, at 8:00 AM ET, featuring key company executives and analysts from various financial institutions.
The upcoming earnings call for GoodRx will provide crucial insights into the company's financial performance and future outlook, impacting stock valuation and investor sentiment.
GoodRx Holdings, Inc. reported Q4 2024 revenue of $198.6 million, with a net income of $6.7 million (3.4% margin) and adjusted EBITDA of $67.1 million.
GoodRx's Q4 and full-year 2024 financial results show strong revenue growth and profitability, indicating solid business performance and potential for future investment returns.
GoodRx Holdings, Inc. (GDRX) reported quarterly earnings of $0.09 per share, matching the Zacks Consensus Estimate and up from $0.08 per share year-over-year.
GoodRx's earnings meet expectations and show year-over-year growth, indicating stability and potential for future performance, which can influence investor sentiment and stock valuation.
GoodRx's Q4 2024 results show performance metrics compared to Wall Street estimates and year-ago values, indicating potential areas of interest for investors.
GoodRx's performance relative to Wall Street estimates and previous year metrics can indicate growth trends and market positioning, influencing investor sentiment and stock valuation.
Frequently Asked Questions About GDRX Stock
What is GoodRx Holdings Inc.'s (GDRX) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, GoodRx Holdings Inc. (GDRX) has a median price target of $6.50. The highest price target is $9.00 and the lowest is $4.75.
Is GDRX stock a good investment in 2025?
According to current analyst ratings, GDRX has 9 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDRX stock?
Wall Street analysts predict GDRX stock could reach $6.50 in the next 12 months. This represents a 47.1% increase from the current price of $4.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GoodRx Holdings Inc.'s business model?
GoodRx operates by aggregating pricing data from over 70,000 pharmacies, allowing users to find discounts, coupons, and compare medication prices. The company generates revenue primarily through partnerships with pharmacies and pharmaceutical companies, receiving fees for each transaction facilitated via its platform.
What is the highest forecasted price for GDRX GoodRx Holdings Inc.?
The highest price target for GDRX is $9.00 from Scott Schoenhaus at Keybanc, which represents a 103.6% increase from the current price of $4.42.
What is the lowest forecasted price for GDRX GoodRx Holdings Inc.?
The lowest price target for GDRX is $4.75 from at , which represents a 7.5% increase from the current price of $4.42.
What is the overall GDRX consensus from analysts for GoodRx Holdings Inc.?
The overall analyst consensus for GDRX is bullish. Out of 25 Wall Street analysts, 9 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $6.50.
How accurate are GDRX stock price projections?
Stock price projections, including those for GoodRx Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
